These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 31295061)

  • 1. Antimicrobial Susceptibility and Molecular Epidemiology of
    Lin MF; Liou ML; Kuo CH; Lin YY; Chen JY; Kuo HY
    Microb Drug Resist; 2019 Nov; 25(9):1338-1346. PubMed ID: 31295061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial susceptibilities of Proteus mirabilis: a longitudinal nationwide study from the Taiwan surveillance of antimicrobial resistance (TSAR) program.
    Wang JT; Chen PC; Chang SC; Shiau YR; Wang HY; Lai JF; Huang IW; Tan MC; Lauderdale TL;
    BMC Infect Dis; 2014 Sep; 14():486. PubMed ID: 25192738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular drivers of emerging multidrug resistance in Proteus mirabilis clinical isolates from Algeria.
    Boudjemaa H; Allem R; Fonkou MDM; Zouagui S; Khennouchi NCEH; Kerkoud M
    J Glob Antimicrob Resist; 2019 Sep; 18():249-256. PubMed ID: 30797091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapidly spreading CTX-M-type beta-lactamase-producing Proteus mirabilis in Japan.
    Kanayama A; Iyoda T; Matsuzaki K; Saika T; Ikeda F; Ishii Y; Yamaguchi K; Kobayashi I
    Int J Antimicrob Agents; 2010 Oct; 36(4):340-2. PubMed ID: 20609568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Properties of multidrug-resistant, ESBL-producing Proteus mirabilis isolates and possible role of beta-lactam/beta-lactamase inhibitor combinations.
    Luzzaro F; Perilli M; Amicosante G; Lombardi G; Belloni R; Zollo A; Bianchi C; Toniolo A
    Int J Antimicrob Agents; 2001 Feb; 17(2):131-5. PubMed ID: 11165117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Plasmid-mediated AMPc producing Proteus mirabilis in the Health Care Area of Santiago de Compostela: molecular and epidemiological analysis by rep-PCR and MALDI-TOF].
    Treviño M; Navarro D; Barbeito G; Areses P; García-Riestra C; Regueiro BJ
    Rev Esp Quimioter; 2012 Jun; 25(2):122-8. PubMed ID: 22707100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nosocomial outbreak by Proteus mirabilis producing extended-spectrum beta-lactamase VEB-1 in a Korean university hospital.
    Kim JY; Park YJ; Kim SI; Kang MW; Lee SO; Lee KY
    J Antimicrob Chemother; 2004 Dec; 54(6):1144-7. PubMed ID: 15546971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissemination of Proteus mirabilis isolates harboring CTX-M-14 and CTX-M-3 beta-lactamases at 2 hospitals in Taiwan.
    Wu LT; Wu HJ; Chung JG; Chuang YC; Cheng KC; Yu WL
    Diagn Microbiol Infect Dis; 2006 Feb; 54(2):89-94. PubMed ID: 16406185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular epidemiology and antimicrobial susceptibility of AmpC- and/or extended-spectrum (ESBL) ß-lactamaseproducing Proteus spp. clinical isolates in Zenica-Doboj Canton, Bosnia and Herzegovina.
    Uzunović S; Ibrahimagić A; Hodžić D; Bedenić B
    Med Glas (Zenica); 2016 Aug; 13(2):103-12. PubMed ID: 27313108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergence of multidrug-resistant Proteus mirabilis in a long-term care facility in Croatia.
    Bedenić B; Firis N; Elveđi-Gašparović V; Krilanović M; Matanović K; Štimac I; Luxner J; Vraneš J; Meštrović T; Zarfel G; Grisold A
    Wien Klin Wochenschr; 2016 Jun; 128(11-12):404-13. PubMed ID: 27220339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regional outbreak of CTX-M-2 β-lactamase-producing Proteus mirabilis in Japan.
    Nakano R; Nakano A; Abe M; Inoue M; Okamoto R
    J Med Microbiol; 2012 Dec; 61(Pt 12):1727-1735. PubMed ID: 22935848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regional Spread of CTX-M-2-Producing Proteus mirabilis with the Identical Genetic Structure in Japan.
    Kato K; Matsumura Y; Yamamoto M; Nagao M; Takakura S; Ichiyama S
    Microb Drug Resist; 2017 Jul; 23(5):590-595. PubMed ID: 27834610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial susceptibility of clinical Enterobacteriaceae isolates at the emergency department in a regional hospital: A threat of extended spectrum beta-lactamase-producers among nursing home residents.
    Liu HC; Hung YP; Lin HJ; Liu HC; Lee JC; Wu YH; Li CW; Li MC; Ko WC
    J Microbiol Immunol Infect; 2016 Aug; 49(4):584-90. PubMed ID: 26692184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular epidemiology of CTX-M-type extended-spectrum β-lactamase-producing Proteus mirabilis isolates in Taiwan.
    Huang CW; Chien JH; Peng RY; Tsai DJ; Li MH; Lee HM; Lin CF; Lee MC; Liao CT
    Int J Antimicrob Agents; 2015 Jan; 45(1):84-5. PubMed ID: 25446905
    [No Abstract]   [Full Text] [Related]  

  • 15. Spread of multidrug-resistant Proteus mirabilis isolates producing an AmpC-type beta-lactamase: epidemiology and clinical management.
    Luzzaro F; Brigante G; D'Andrea MM; Pini B; Giani T; Mantengoli E; Rossolini GM; Toniolo A
    Int J Antimicrob Agents; 2009 Apr; 33(4):328-33. PubMed ID: 19095415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Characterization of β-Lactam Resistance and Antimicrobial Susceptibility to Possible Therapeutic Options of AmpC-Producing Multidrug-Resistant
    Rubic Z; Soprek S; Jelic M; Novak A; Goic-Barisic I; Radic M; Tambic-Andrasevic A; Tonkic M
    Microb Drug Resist; 2021 Feb; 27(2):162-169. PubMed ID: 32429775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum β-lactamases in China.
    Yang Q; Zhang H; Cheng J; Xu Z; Xu Y; Cao B; Kong H; Ni Y; Yu Y; Sun Z; Hu B; Huang W; Wang Y; Wu A; Feng X; Liao K; Shen D; Hu Z; Chu Y; Lu J; Su J; Gui B; Duan Q; Zhang S; Shao H
    Int J Antimicrob Agents; 2015 May; 45(5):485-90. PubMed ID: 25600890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution and antimicrobial susceptibility profile of extended-spectrum β-lactamase-producing Proteus mirabilis strains recently isolated in Japan.
    Kanayama A; Kobayashi I; Shibuya K
    Int J Antimicrob Agents; 2015 Feb; 45(2):113-8. PubMed ID: 25182712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular diversity of Proteus mirabilis isolates producing extended-spectrum beta-lactamases in a French university hospital.
    Biendo M; Thomas D; Laurans G; Hamdad-Daoudi F; Canarelli B; Rousseau F; Castelain S; Eb F
    Clin Microbiol Infect; 2005 May; 11(5):395-401. PubMed ID: 15819867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between the distribution of cefepime minimum inhibitory concentrations and detection of extended-spectrum β-lactamase production among clinically important Enterobacteriaceae isolates obtained from patients in intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2007.
    Jean SS; Lee WS; Bai KJ; Lam C; Hsu CW; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Chen RJ; Hsueh PR
    J Microbiol Immunol Infect; 2015 Feb; 48(1):85-91. PubMed ID: 23973410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.